TW200500085A - Sustained-release pharmaceutical composition for lung administration - Google Patents

Sustained-release pharmaceutical composition for lung administration

Info

Publication number
TW200500085A
TW200500085A TW093104753A TW93104753A TW200500085A TW 200500085 A TW200500085 A TW 200500085A TW 093104753 A TW093104753 A TW 093104753A TW 93104753 A TW93104753 A TW 93104753A TW 200500085 A TW200500085 A TW 200500085A
Authority
TW
Taiwan
Prior art keywords
sustained
pharmaceutical composition
release pharmaceutical
lung administration
active substance
Prior art date
Application number
TW093104753A
Other languages
English (en)
Chinese (zh)
Other versions
TWI332403B (enExample
Inventor
Akira Yamamoto
Keigo Yamada
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of TW200500085A publication Critical patent/TW200500085A/zh
Application granted granted Critical
Publication of TWI332403B publication Critical patent/TWI332403B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW093104753A 2003-02-26 2004-02-25 Sustained-release pharmaceutical composition for lung administration TW200500085A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003049019 2003-02-26

Publications (2)

Publication Number Publication Date
TW200500085A true TW200500085A (en) 2005-01-01
TWI332403B TWI332403B (enExample) 2010-11-01

Family

ID=32923305

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093104753A TW200500085A (en) 2003-02-26 2004-02-25 Sustained-release pharmaceutical composition for lung administration

Country Status (9)

Country Link
US (1) US20060078504A1 (enExample)
EP (1) EP1600170A4 (enExample)
JP (1) JPWO2004075920A1 (enExample)
KR (1) KR20050105490A (enExample)
CN (1) CN1744917B (enExample)
CA (1) CA2512434C (enExample)
MY (1) MY142361A (enExample)
TW (1) TW200500085A (enExample)
WO (1) WO2004075920A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130150810A1 (en) * 2002-04-30 2013-06-13 The Population Council, Inc. Intravaginal ring for the delivery of unique combinations of antimicrobial compositions
US20080131454A1 (en) * 2006-12-05 2008-06-05 Marinomed Biotechnologie Gmbh Methods and Compositions for the Treatment of Rhinovirus Infections with Carrageenan
HRP20130402T1 (hr) * 2007-08-24 2013-06-30 Marinomed Biotechnologie Gmbh Antivirusni pripravak koji sadrži sulfatirani polisaharid: jota-karagenan
CN102065869B (zh) * 2008-07-01 2014-10-08 玛丽诺姆德生物技术公司 抗过敏的海洋生物聚合物
EP2233130A1 (en) * 2009-03-23 2010-09-29 Genepharm (Europe) Trading Limited A sustained release oral composition of an antipsychotic agent
CN114191418B (zh) * 2021-12-21 2023-06-09 丽珠医药集团股份有限公司 噻托溴铵双层微球及其制备方法和噻托溴铵缓释吸入剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5200195A (en) * 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
KR100208979B1 (ko) 1992-06-12 1999-07-15 야스이 쇼사꾸 기도내 투여용 제제
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
JP2000070327A (ja) * 1998-09-01 2000-03-07 Kao Corp 鼻腔内洗浄具
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US6461639B2 (en) * 2000-05-01 2002-10-08 Aeropharm Technology, Inc. Core formulation
NL1015288C2 (nl) * 2000-05-24 2001-12-14 Peter Ferdinand Elbers Preparaat voor het stabiliseren van de beschermlaag op het epitheel van het hoornvlies of de longblaasjes.
US6749845B2 (en) * 2001-02-15 2004-06-15 Aeropharm Technology, Inc. Modulated release particles for lung delivery
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6551578B2 (en) * 2001-02-15 2003-04-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
JP2002255852A (ja) * 2001-03-01 2002-09-11 Toa Eiyo Ltd 口内炎用スプレー製剤
JP2004529929A (ja) * 2001-04-23 2004-09-30 ニュクリスト ファーマシューティカルズ コーポレーション アポトーシスの誘導およびマトリックスメタロプロテイナーゼの阻害のための金属の使用
JP2003040766A (ja) * 2001-07-26 2003-02-13 Kao Corp 鼻腔内洗浄具

Also Published As

Publication number Publication date
HK1083768A1 (zh) 2006-07-14
TWI332403B (enExample) 2010-11-01
WO2004075920A1 (ja) 2004-09-10
JPWO2004075920A1 (ja) 2006-06-01
KR20050105490A (ko) 2005-11-04
CA2512434C (en) 2012-01-03
MY142361A (en) 2010-11-30
EP1600170A4 (en) 2010-12-29
CA2512434A1 (en) 2004-09-10
US20060078504A1 (en) 2006-04-13
CN1744917B (zh) 2010-05-05
CN1744917A (zh) 2006-03-08
EP1600170A1 (en) 2005-11-30

Similar Documents

Publication Publication Date Title
AP1760A (en) Platinum derivative pharmaceutical formulations.
SE0102276D0 (sv) Device and method for the administration of a medicament
EP1477119A4 (en) METHOD FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS
EP1708685A4 (en) GALENIC FORMS OF EFFERVESCENT ORAL OPIATES AND METHODS OF ADMINISTERING OPIATES
PL374443A1 (en) Novel pyrimidineamide derivatives and the use thereof
TW200738228A (en) Neramexane modified release matrix tablet
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
DE50313292D1 (de) Vernebelbare liposomen und ihre verwendung zur pulmonalen applikation von wirkstoffen
GB2446341A (en) Method and system for transdermal drug delivery
WO2004112838A3 (en) Codrugs of diclofenac
GR1004193B (el) Φαρμακευτικη συνθεση περιεχουσα σιταλοπραμη
EA200700158A1 (ru) Лекарственные формы с ядром таблетки, покрытым энтеросолюбильной оболочкой
TW200500085A (en) Sustained-release pharmaceutical composition for lung administration
SI1596841T1 (sl) Terapevtski sistem amoksicilina in klavulanske kisline
TW200517127A (en) Novel composition
UA90504C2 (ru) Лекарственное средство для лечения заболеваний дыхательных путей
TW200509984A (en) Injectable dosage form of flupirtine
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
ATE256134T1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
SG146631A1 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
UA87152C2 (ru) Твердая фармацевтическая композиция, содержащая миртазапин, и способ ее получения
CA2532714A1 (en) Oral sustained-release tablet comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide
GB9917290D0 (en) Pharmaceutical composition
TW200633722A (en) Complexes made using low solubility drugs

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees